NMB4.0: development of integrated nuclear fuel cycle simulator from the front to back-end

Nuclear Material Balance code version 4.0 (NMB4.0) has been developed through collaborative R&D between TokyoTech&JAEA. Conventional nuclear fuel cycle simulation codes mainly analyze actinides and are specialized for front-end mass balance analysis. However, quantitative back-end simulation has recently become necessary for considering R&D strategies and sustainable nuclear energy utilization. Therefore, NMB4.0 was developed to realize the integrated nuclear fuel cycle simulation from front- to back-end. There are three technical features in NMB4.0: 179 nuclides are tracked, more than any other code, throughout the nuclear fuel cycle; the Okamura explicit method is implemented, which contributes to reducing the numerical cost while maintaining the accuracy of depletion calculations on nuclides with a shorter half-life; and flexibility of back-end simulation is achieved. The main objective of this paper is to show the newly developed functions, made for integrated back-end simulation, and verify NMB4.0 through a benchmark study to show the computational performance.

Prevention of rotavirus infection by oral administration of cow colostrum containing antihumanrotavirus antibody

After immunizing 8-month pregnant Holstein cows with human rotavirus, Wa strain, cow colostrum containing neutralizing antibody to human rotavirus, designated as Rota colostrum, was obtained. After randomly grouping 13 infants from a single orphanage, 6 infants received 20 ml of Rota colostrum every morning and 7 control infants received 20 ml of market milk. One month later, rotavirus associated diarrhea was observed in 6 of the 7 infants given milk and 1 out of the 6 infants given Rota colostrum. Orally administered Rota colostrum significantly protected infants from diarrhea caused by rotavirus (P less than 0.05). Two out of 5 Rota colostrum recipients who were free from diarrhea showed rises in complement fixation (CF) antibody titer after the rotavirus infection epidemic. Thus, Rota colostrum prevented the outbreak of diarrhea but did not prevent immunological responses to natural rotavirus infection. In the therapeutic trial Rota colostrum had no effect on duration of diarrhea, bowel movements or virus shedding in stool. However, there were no side-effects of Rota colostrum.